Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial

OBJECTIVE: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1–3. This analysis compared efficacy and safety of axitinib plus gemcitabine in patients with advanced pancreatic cancer from Japan, North America and the European Union, enrolled in a randomized...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Jpn J Clin Oncol
Prif Awduron: Ioka, Tatsuya, Okusaka, Takuji, Ohkawa, Shinichi, Boku, Narikazu, Sawaki, Akira, Fujii, Yosuke, Kamei, Yoichi, Takahashi, Satori, Namazu, Katsushi, Umeyama, Yoshiko, Bycott, Paul, Furuse, Junji
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2015
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4412139/
https://ncbi.nlm.nih.gov/pubmed/25647781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyv011
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg